Equities research analysts at Deutsche Bank assumed coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research report issued to clients and investors on Tuesday. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Several other research analysts have also commented on the stock. BidaskClub lowered shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Leerink Swann restated a “hold” rating and set a $60.00 price target on shares of Intercept Pharmaceuticals in a research note on Tuesday, November 28th. Wedbush restated a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Monday, November 20th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $144.13.
Shares of Intercept Pharmaceuticals (ICPT) traded down $0.70 on Tuesday, hitting $60.64. 353,697 shares of the stock traded hands, compared to its average volume of 765,504. Intercept Pharmaceuticals has a 52-week low of $54.98 and a 52-week high of $135.59. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million during the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. Intercept Pharmaceuticals’s revenue was up 697.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.59) EPS. equities analysts expect that Intercept Pharmaceuticals will post -13.35 EPS for the current year.
In other news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 2,566 shares of company stock worth $151,025. Insiders own 4.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in ICPT. Senvest Management LLC acquired a new stake in Intercept Pharmaceuticals during the third quarter worth about $33,883,000. Balyasny Asset Management LLC acquired a new stake in Intercept Pharmaceuticals during the second quarter worth about $13,766,000. Vanguard Group Inc. increased its position in shares of Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares during the last quarter. First Trust Advisors LP increased its position in shares of Intercept Pharmaceuticals by 17.0% during the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after acquiring an additional 41,856 shares during the last quarter. Finally, Quantitative Investment Management LLC acquired a new stake in shares of Intercept Pharmaceuticals during the second quarter valued at about $3,728,000. Hedge funds and other institutional investors own 73.80% of the company’s stock.
WARNING: “Intercept Pharmaceuticals (ICPT) Coverage Initiated by Analysts at Deutsche Bank” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/12/intercept-pharmaceuticals-icpt-coverage-initiated-by-analysts-at-deutsche-bank.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.